In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Patients with obesity and comorbid cardiovascular disease were more likely to ration prescription drugs than those without obesity.

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor a ...

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?